H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT
Selvaraju highlighted the upcoming release of top-line data from the Phase 3 VELA program for Sonelokimab as a major catalyst for the company.
Moonlake Immunotherapeutics (MLTX)
Market is closed
Sector: Investment Advice
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 19,751,284 | $771,682,666 | 31.45% | |
| 2. | Cormorant Asset Management Bihua Chen | 8,494,151 | $331,866,480 | 24.95% | |
| 3. | VenBio Select Advisor Kurt Von Emster | 2,770,100 | $108,227,807 | 1.69% | |
| 4. | Citadel Investment Group Ken Griffin | 1,478,635 | $57,770,270 | -33% | 0.01% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,100,000 | $42,977,000 | 0.26% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $59.90 | 58,839 | $3,524,297.23 | 8,494,151 | 2023-10-05 | Filing | |
| $57.32 | 67,814 | $3,887,017.10 | 8,435,312 | 2023-10-04 | Filing | |
| $57.25 | 150,487 | $8,615,681.72 | 8,367,498 | 2023-10-03 | Filing | |
| $57.37 | 74,911 | $4,297,644.07 | 8,217,011 | 2023-10-02 | Filing | |
| $50.00 | 800,000 | $40,000,000.00 | 4,927,100 | 2023-06-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.00 | 132,549 | $6,627,662.08 | 1,287,768 | 2024-10-04 | Filing | |
| $50.00 | 836,862 | $41,844,438.98 | 8,168,838 | 2024-10-04 | Filing | |
| $50.00 | 1,030,589 | $51,531,098.94 | 10,235,089 | 2024-10-04 | Filing | |
| $53.72 | 171,000 | $9,186,120.00 | 171,980 | 2024-10-04 | Filing | |
| $55.89 | 4,740 | $264,918.60 | 2,982,814 | 2024-02-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,327,014 | $247,196,447 | 0.02% | |
| 2. | 1,434,770 | $56,056,464 | 0.27% | |
| 3. | 1,292,608 | $50,502,195 | 0.01% | |
| 4. | 1,269,351 | $49,593,543 | 0.11% | |
| 5. | 966,090 | $37,745,136 | 0.01% |
News See All
11 Best Guru Stocks to Buy According to Wall Street Analysts
Wall Street seems to be breathing a little easier after the initial panic over President Trump’s tariffs earlier this month, but the rollercoaster is not over just yet.
10 Oversold Biotech Stocks to Buy Now
Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.
10 Oversold Pharma Stocks to Buy According to Analysts
On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity...
12 Most Oversold Healthcare Stocks to Buy Now
Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion in 2023, up 7.5% from 2022.
10 Best Guru Stocks To Buy Now
Due to the plethora of investment options such as equities, bonds, and mutual funds that are available today, picking the right set of vehicles to either preserve or grow money can often seem to be a ...
10 Worst ADR Stocks To Buy According to Short Sellers
An American Depositary Receipt (ADR) is a certificate issued by a U.S. bank that represents shares of a foreign company. These certificates allow U.S.
Oppenheimer's Favorite Stocks For Next 12 Months: Top 32 Stock Picks
The tail end of August is appearing to turn a fresh page for Wall Street.
5 Best Performing NASDAQ Stocks in 2023
In this piece, we will take a look at the five best performing NASDAQ stocks in 2023.
5 Best Performing Biotech Stocks in 2023
In this piece, we will take a look at the five best performing biotechnology stocks in 2023.
Billionaire Hedge Funds
